Ads
related to: dabigatran etexilate
Search results
Results from the WOW.Com Content Network
Dabigatran, sold under the brand name Pradaxa among others, is an anticoagulant used to treat and prevent blood clots and to prevent stroke in people with atrial fibrillation. [ 6 ] [ 7 ] Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. [ 6 ]
In October 2010 the US FDA approved dabigatran etexilate for the prevention of stroke in patients with atrial fibrillation (AF). [6] [10] Many pharmaceutical companies have attempted to develop orally bioavailable DTI drugs but dabigatran etexilate is the only one to reach the market. [9]
Dabigatran etexilate. In terms of treatment for protein S deficiency the following are consistent with the management (and administration of) individuals with this condition (the prognosis for inherited homozygotes is usually in line with a higher incidence of thrombosis for the affected individual [1]): [2] [10] Unfractionated heparin (w ...
Dabigatran etexilate is a common example which has a rapid onset of action. [40] Whereas direct factor Xa inhibitors including apixaban and rivaroxaban directly bind to clotting factor Xa to block its activity, thus inhibiting thrombin formation. [34]
Dabigatran is an oral direct thrombin inhibitor. Dabigatran (Pradaxa) was found to be noninferior to Warfarin in prevention of ischemic stroke, as well as intracranial hemorrhage risk and overall mortality for non-valvular atrial fibrillation according to the RE-LY trial.
Idarucizumab is a monoclonal antibody, approved by the US FDA in 2015, that reverses the effect of dabigatran by binding to both free and thrombin-bound dabigatran. [ 116 ] [ 117 ] Andexanet alfa is a recombinant modified human factor Xa decoy that reverses the effect of factor Xa inhibitors by binding at the active sites of factor Xa inhibitor ...
[35] [37] These direct factor Xa inhibitors can be administered orally, as can dabigatran etexilate, which is a direct thrombin inhibitor. Fondaparinux, Rivaroxaban, Apixaban, Dabigatran Etexilate and Edoxaban are currently used as FDA-approved anticoagulant drugs. Development of Idraparinux was discontinued. [38]
Dabigatran etexilate is a direct oral thrombin inhibitor that has been approved as a substitute for warfarin in preventing stroke in patients with nonvalvular atrial fibrillation. It is also used to treat deep venous thrombosis and pulmonary embolism, and to reduce the risk of recurrence.
Ads
related to: dabigatran etexilate